Oncolytics Biotech (NASDAQ:ONCY) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a report issued on Monday morning,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

Several other brokerages also recently issued reports on ONCY. Royal Bank of Canada reduced their price target on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating for the company in a report on Monday. Leede Financial lowered shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. Finally, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th. Three research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $4.00.

Oncolytics Biotech Price Performance

NASDAQ:ONCY opened at $0.64 on Monday. The firm has a market capitalization of $54.89 million, a P/E ratio of -2.38 and a beta of 1.18. The business has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $0.93. Oncolytics Biotech has a 12-month low of $0.60 and a 12-month high of $1.53.

Institutional Investors Weigh In On Oncolytics Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of ONCY. International Assets Investment Management LLC grew its position in Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after buying an additional 26,069 shares in the last quarter. Vantage Point Financial LLC acquired a new stake in shares of Oncolytics Biotech in the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new position in shares of Oncolytics Biotech in the fourth quarter valued at approximately $90,000. National Bank of Canada FI increased its stake in shares of Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after acquiring an additional 42,955 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after purchasing an additional 24,997 shares in the last quarter. 6.82% of the stock is currently owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.